TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8033939
Drug: Antiplatelet medication
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet medication
Study: 8145910
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) 0.4 g/kg body weight per day for 5 consecutive days
Study: 8602598
Drug: Gum arabic
Normalized name: Gum arabic
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum arabic (50 g/d)
Study: 19695030
Drug: Olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40 mg administered at bedtime
Study: 16495014
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), 4 sessions
Study: 23337270
Drug: Ankle block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ankle block administered after inflation of tourniquet (Group A)
Study: 10827332
Drug: Norplant(R) contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norplant(R) contraceptive implants
Study: 25963064
Drug: Beta Blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta Blocker Therapy
Study: 1974070
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg lorazepam
Study: 12424549
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg lorazepam
Study: 22273498
Drug: 800-nm diode
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800-nm diode laser treatment
Study: 31067358
Drug: High-dose interferon-α
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon-α (HDI)
Study: 22196464
Drug: Transfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion of a fixed dose of 12 ml/kg of FFP
Study: 31508999
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation plus oral antibiotic bowel preparation (neomycin and metronidazole)
Study: 29112565
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation
Study: 3297375
Drug: Sublingual lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual lorazepam combined with high-dose metoclopramide (3 mg/kg) infused twice 3 h apart with i.v. dexamethasone
Study: 24667161
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate 2 g/day
Study: 21529957
Drug: pegaptanib 0.3
Normalized name: PEGAPTANIB 0.3MG/0.09ML INTRAOCULAR SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegaptanib 0.3 mg
Study: 18408387
Drug: Amodiaquine (AMQ)
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine (AMQ) alone (10 mg AMQ base/kg daily for 3 days)
Study: 18408387
Drug: Amodiaquine (AMQ)
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine (AMQ) plus chlorpheniramine (CP) (AMQCP) for 7 days (10 mg AMQ base/kg daily for 3 days)
Study: 8723574
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (300 to 600 IU/kg twice weekly for 3 weeks)
Study: 28893208
Drug: Intravenous patisiran
Normalized name: patisiran
DrugBank: Patisiran (DB14582)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous patisiran 0.3 mg/kg once every 3 weeks
Study: 24170814
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (FCM) at an initial dose of 200 mg with subsequent dosing as necessary to target serum ferritin 100-200 µg/L
Study: 15165944
Drug: Antegrade glutamate
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antegrade glutamate and aspartate (15 mmol/L) enriched cold crystalloid cardioplegia
Study: 30701661
Drug: Method of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method of Levels (MOL) therapy
Study: 15563363
Drug: Multidisciplinary service
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary service model delivering medication review
Study: 16234453
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (Control)
Study: 20368068
Drug: Lian propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lian propofol TCI system (6 microg/ml initial target plasma concentration)
Study: 18060419
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) without alendronate
Study: 18060419
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) with alendronate
Study: 16127039
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg administered enterally
Study: 11678947
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray
Study: 6897633
Drug: Treatment schedule
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment schedule C (Intermittent high-dose prednimustine)
Study: 1428773
Drug: Indomethacin and
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin and Ethamsylate combination therapy
Study: 12131732
Drug: Combined magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined magnetic field device (30-minute treatment per day for 9 months)
Study: 31594077
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (3-5 MIU/m(2), once daily) in combination with lamivudine for 12 weeks; followed by lamivudine for 24 weeks after interferon discontinuation.
Study: 12771706
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg intravenously every 3 months for 1 year)
Study: 402663
Drug: d- and
Normalized name: Folic acid- and iron-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: d- and l-amphetamine combined with lithium
Study: 11052960
Drug: Hypoglycemia of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia of 70 mg/dl
Study: 17140543
Drug: Xylitol tablets
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol tablets
Study: 20139789
Drug: Jumping twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jumping twice daily (J2x)
Study: 12575551
Drug: Combined medication
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined medication of Songling Xue-maikang Capsule (SXC) with captopril
Study: 15877875
Drug: Pericarp seed
Normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pericarp seed coat (PCS) - 175 g bread made with PCS flour and placebo tablet each day
Study: 25992639
Drug: Zidovudine monotherapy
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine monotherapy
Study: 1424620
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive (ethinyl estradiol and gestodene)
Study: 11783838
Drug: Systemic growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic growth hormone for fibromyalgia
Study: 11783838
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine for fibromyalgia
Study: 30744676
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture with placebo herbal medicine
Study: 15210261
Drug: Cognitive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive group (12 min preparation with sensory and procedural information)
Study: 24935082
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management only
Study: 8144233
Drug: Cobalt chloride
Normalized name: Cobalt chloride
DrugBank: Cobalt chloride (DB14206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobalt chloride (soluble cobalt compound)
Study: 3513714
Drug: Rotahaler treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotahaler treatment
Study: 22669334
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) at increasing doses (2 gr/day) for 5-15 days prior to surgical resection
Study: 17601993
Drug: Acipimox treatment
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox treatment
Study: 12874489
Drug: Clonidine syrup
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine syrup 0.10 to 0.20 mg/day
Study: 31470366
Drug: Royal jelly
Normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Royal jelly (1000 mg daily for eight weeks)
Study: 30717034
Drug: Various interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various interventions related to management of hydrocephalus (e.g., shunt techniques, endoscopic treatment)
Study: 11856590
Drug: Evaluation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of high-dose chemotherapy strategy
Study: 12916293
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bisphosphonates with estrogen or raloxifene
Study: 26358841
Drug: OKZ 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKZ 60 mg/120 mg every two weeks (Q2W)
Study: 17986538
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin ointment applied once daily after routine dressing (Group M)
Study: 18258295
Drug: Resin cement
Normalized name: Quick Cure resin cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin cement (Rely‐X Arc, 3M) with no surface treatment (Group E)
Study: 12634979
Drug: Dexamethasone (DEXA)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEXA) 2.0 mg i.v.
Study: 9596865
Drug: Methyl carprost
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl carprost suppository (vaginal administration)
Study: 9596865
Drug: Methyl carprost
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl carprost suppository (rectal administration)
Study: 8033499
Drug: Nicotine skin
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine skin patch plus placebo
Study: 2529815
Drug: Teicoplanin in
Normalized name: teicoplanin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin in combination with aminoglycoside
Study: 28625750
Drug: 24-hour postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24-hour postoperative albumin <3.0 g/dL
Study: 26047975
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg TA-8995
Study: 8072050
Drug: Low-dose methadone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methadone (40 mg)
Study: 29316405
Drug: Magnesium-zinc-calcium-vitamin D
Normalized name: calcium carbonate / magnesium oxide / zinc oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium-zinc-calcium-vitamin D co-supplements
Study: 8658373
Drug: ANP 5
Normalized name: Atrial Natriuretic Peptide
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANP 5 mg alone
Study: 10975210
Drug: Animal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Animal insulin
Study: 3610510
Drug: Similar solution
Normalized name: Antigonadotropins and similar agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar solution without the active substance (Control)
Study: 14558184
Drug: Increasing number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing number of other concomitant medications
Study: 10846306
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy for adolescents (CBGT‐A)
Study: 19835725
Drug: Gel plus
Normalized name: Magagel Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel plus SLS
Study: 16522914
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg Ca/d (as calcium carbonate)
Study: 12536052
Drug: Valproate sodium
Normalized name: Valproate Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate sodium infused at 3.0 mg/kg/min
Study: 12536052
Drug: Valproate sodium
Normalized name: Valproate Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate sodium infused at 1.5 mg/kg/min
Study: 7816415
Drug: Intraoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative administration of mitomycin C (4% solution, applied for 3 min)
Study: 3290427
Drug: Sanguinarine-containing dentifrice
Normalized name: sanguinarine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanguinarine-containing dentifrice (750 mcg/g)
Study: 16607096
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of hormone therapy (HT) in women aged 70-79 years
Study: 9129372
Drug: Adult Attachment
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult Attachment Interview administered after intervention.
Study: 20060665
Drug: Daily cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cholecalciferol 800 IU + calcium carbonate 1000 mg
Study: 10086969
Drug: Etilefrine at
Normalized name: etilefrine
DrugBank: Etilefrine (DB08985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etilefrine at a dosage of 75 mg/d
Study: 6754511
Drug: Alclometasone dipropionate
Normalized name: Alclometasone Dipropionate
DrugBank: Alclometasone (DB00240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alclometasone dipropionate ointment (0.05%) applied twice daily for 3 weeks
Study: 8104017
Drug: Ebastine 10
Normalized name: ebastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10 mg
Study: 2905151
Drug: Ebastine 50
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 50 mg
Study: 25083090
Drug: Biofeedback-guided pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback-guided pelvic floor exercise therapy (BFT)
Study: 24970885
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (RAS inhibitors only)
Study: 23652031
Drug: Progesterone cream
Normalized name: NATURAL PROGESTERONE CREAM,TOP
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone cream (80 mg applied daily for 14 days)
Study: 27107025
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) using Japanese cedar (JC) pollen extract
Study: 25099545
Drug: Intraduodenal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal protein infusion (hydrolyzed whey) 90 kcal
Study: 8430051
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) MPH
Study: 9333057
Drug: Intravenous levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous levofloxacin 500 mg
Study: 9333057
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin formulations
Study: 9333057
Drug: Intravenous levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous levofloxacin infusion
Study: 18705297
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei DG 16 billion/day for 10 days/month (group L)
Study: 17184102
Drug: Esterified conjugated
Normalized name: estrogens, conjugated (USP) / estrogens, esterified (USP) / medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified conjugated estrogens (ECE) 0.156 mg/day (ultra low‐dose) (n = 18)
Study: 20018535
Drug: Intrathecal methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal methylprednisolone (60 mg)
Study: 31646623
Drug: Free nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Free nicotine patches
Study: 12027474
Drug: conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional treatment
Study: 8580574
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LPD; median 0.84 g.kg-1.day-1)
Study: 8580574
Drug: Medium-protein diet
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-protein diet (MPD; median 1.33 g.kg-1.day-1)
Study: 8580574
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (HPD; median 2.05 g.kg-1.day-1)
Study: 2406856
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (BSS) at a dosage of 100 mg/(kg.d) for 5 days
Study: 11421145
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (listening to music of their choice via audiotapes and headphones before and during simulation and daily treatments)
Study: 28556284
Drug: Tadalafil plus
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil plus α1-blocker combination therapy
Study: 25583727
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of ceftazidime
Study: 25583727
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of ceftazidime
Study: 20486839
Drug: Lisinopril (control)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (control)
Study: 7485007
Drug: Levosulpiride 25
Normalized name: Levosulpiride 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride 25 mg t.i.d.
Study: 21823120
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus chemotherapy
Study: 29396094
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance therapy
Study: 16338502
Drug: Assessment and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment and case management for 6 months (treatment group)
Study: 22563440
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole 5 mg/kg/d for 24 weeks
Study: 9464734
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg nitroglycerin
Study: 9464734
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg nitroglycerin
Study: 12220477
Drug: Oral provocation
Normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral provocation tests (OPT) for paracetamol hypersensitivity
Study: 24242999
Drug: Arterolane (RBx11160)
Normalized name: Arterolane
DrugBank: Arterolane (DB19027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterolane (RBx11160) maleate 25, 50, 100, 150, 200, 300, 400, 600 mg single oral doses
Study: 30672193
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment including internal treatment, acupuncture, and rehabilitation for 2 weeks, 6 times a week, once a day.
Study: 21240683
Drug: Oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate (IBA) 50 mg/day